Phase 3Completed
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
A Phase 3, Randomized, Double-blinded Study to Evaluate the Efficacy and Safety of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (OUTSTAND-2)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. (Industry)
- Enrolment
- 810 enrolled
- Conditions
- Type 2 Diabetes
- Interventions
- HRS-7535 tablet; dapagliflozin tablet
- Ages
- adults, older adults
- Registry
- NCT06589765
Full record on ClinicalTrials.gov
From the registry
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 compared with dapagliflozin in subjects with type 2 diabetes mellitus with inadequate glycemic control using metformin.
Primary outcomes
- Change from baseline in HbA1c at 32 weeks of treatment
History
Last registry update
Primary completion
Started
Registered